JOURNAL OF IMMUNOTHERAPY

Scope & Guideline

Pioneering Insights for Tomorrow's Cancer Treatments

Introduction

Delve into the academic richness of JOURNAL OF IMMUNOTHERAPY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1524-9557
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1991 to 2024
AbbreviationJ IMMUNOTHER / J. Immunother.
Frequency9 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The JOURNAL OF IMMUNOTHERAPY is dedicated to advancing the understanding and application of immunotherapy in cancer treatment. It serves as a platform for researchers and clinicians to share insights into the mechanisms, efficacy, and safety of various immunotherapeutic approaches. The journal's scope encompasses a wide range of topics related to immune modulation in oncology, focusing on both clinical and preclinical studies.
  1. Clinical Efficacy of Immunotherapies:
    The journal publishes studies evaluating the clinical outcomes of various immunotherapeutic agents, including immune checkpoint inhibitors, CAR-T cells, and bispecific antibodies in different cancer types.
  2. Mechanisms of Immune Response:
    Research focused on understanding the biological mechanisms underlying immune responses to cancer therapies is a core area, including studies on immune cell infiltration, tumor microenvironment interactions, and immune signaling pathways.
  3. Adverse Effects and Management:
    The journal addresses the safety and adverse effects associated with immunotherapy, publishing findings on immune-related adverse events and their management strategies.
  4. Biomarkers and Predictive Models:
    There is a strong emphasis on identifying biomarkers that can predict responses to immunotherapy, including genetic, epigenetic, and immune profiling studies.
  5. Innovative Therapeutic Strategies:
    The journal encourages submissions on novel therapeutic strategies that combine immunotherapy with other treatment modalities, such as chemotherapy, targeted therapy, and radiation, to enhance efficacy.
  6. Translational Research:
    The journal bridges the gap between laboratory research and clinical application, promoting studies that translate findings from bench to bedside and enhance patient outcomes.
The JOURNAL OF IMMUNOTHERAPY has identified several trending and emerging themes that are gaining traction in recent publications. These themes reflect the evolving landscape of cancer immunotherapy and highlight areas of growing interest among researchers.
  1. Combination Immunotherapy Approaches:
    There is a notable increase in research focusing on combination therapies that integrate immunotherapy with other treatments, such as chemotherapy and targeted therapies, indicating a trend towards synergistic treatment strategies.
  2. Real-world Evidence Studies:
    Recent publications emphasize the importance of real-world evidence in understanding the effectiveness of immunotherapies outside of clinical trial settings, providing insights into patient demographics and treatment outcomes.
  3. Personalized Immunotherapy:
    Emerging research is increasingly focused on personalized approaches to immunotherapy, including patient-specific biomarker identification and tailored treatment regimens based on individual tumor characteristics.
  4. Microbiome and Immunotherapy Interactions:
    An emerging area of interest involves studying the interactions between the microbiome and immune responses to cancer therapies, highlighting the role of gut health in treatment efficacy.
  5. Novel Immune Modulators:
    The exploration of new immune modulators, such as novel checkpoint inhibitors and bispecific antibodies, is on the rise, showcasing an expanding arsenal of therapeutic options in immuno-oncology.
  6. Long-term Outcomes and Survivorship:
    There is growing attention to the long-term effects of immunotherapy on cancer survivors, including studies on quality of life, late-onset adverse effects, and strategies for post-treatment management.

Declining or Waning

While the JOURNAL OF IMMUNOTHERAPY has experienced growth in various areas, certain themes have shown a decline in publication frequency, reflecting shifts in research focus or saturation of the field.
  1. Traditional Chemotherapy Combinations:
    Research exploring traditional chemotherapy combinations with immunotherapy appears to be waning, as the field shifts towards more innovative combination strategies and personalized approaches.
  2. Basic Immunology Studies:
    The journal has seen a decrease in purely basic immunology studies that do not directly relate to cancer treatment, as the emphasis is increasingly on translational and clinical research.
  3. Older Immunotherapeutic Agents:
    There is less focus on older immunotherapeutic agents that have been largely replaced by newer, more effective therapies. This trend indicates a move towards cutting-edge treatments rather than revisiting past modalities.
  4. Single-agent Immunotherapy Studies:
    As combination therapies gain prominence, studies focusing solely on single-agent immunotherapy outcomes have become less common, reflecting a shift towards integrated treatment approaches.

Similar Journals

JOURNAL OF IMMUNOLOGY

Unveiling the Secrets of Immunity
Publisher: AMER ASSOC IMMUNOLOGISTSISSN: 0022-1767Frequency: 24 issues/year

Welcome to the JOURNAL OF IMMUNOLOGY, a prestigious publication associated with the American Association of Immunologists and dedicated to advancing the field of immunology. With a rich history dating back to 1945, this journal is renowned for its high-impact research, evident in its notable 2023 Q1 rankings in both Immunology and Allergy, as well as its strong positions in Scopus rankings—Rank #68 in Immunology and Allergy and Rank #79 in Immunology and Microbiology. Although it operates on a subscription basis, its commitment to publishing cutting-edge studies ensures that it remains a vital resource for scientists, healthcare professionals, and students alike. As the journal continues to pave the way for innovative research and breakthroughs in immunological science, it facilitates a platform for dialogue and discovery among researchers and practitioners across the globe.

Theranostics

Pioneering Multidisciplinary Approaches in Healthcare.
Publisher: IVYSPRING INT PUBLISSN: 1838-7640Frequency: 1 issue/year

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

MELANOMA RESEARCH

Unveiling Innovations in Skin Cancer Science.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0960-8931Frequency: 6 issues/year

MELANOMA RESEARCH is a leading journal dedicated to the exploration and dissemination of innovative research in the field of melanoma and skin cancers. Published by Lippincott Williams & Wilkins, this journal has been a pivotal resource since its inception in 1991, continually evolving to encompass significant advancements within dermatology and oncology through 2024. With a focus on high-quality, peer-reviewed articles, it offers critical insights into cellular mechanisms, treatment strategies, and emerging therapies pertinent to melanoma. It currently holds a Q3 category in Cancer Research and a Q2 category in Dermatology, while also ranking within the 65th percentile for Medicine Dermatology according to Scopus. Although not an open-access journal, MELANOMA RESEARCH ensures accessibility through various institutional subscriptions, making it an invaluable asset for researchers, professionals, and students engaged in pioneering melanoma research.

Cancer Immunology Research

Driving Progress in Cancer Treatment through Immunology
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2326-6066Frequency: 12 issues/year

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.

HEMATOLOGICAL ONCOLOGY

Pioneering Insights in Oncology and Hematology
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Frontiers in Immunology

Leading the Charge in Immunological Research and Discovery
Publisher: FRONTIERS MEDIA SAISSN: 1664-3224Frequency: 1 issue/year

Frontiers in Immunology is a leading open-access journal published by FRONTIERS MEDIA SA since 2010, dedicated to advancing knowledge in the field of immunology. With an impressive Q1 ranking in both Immunology and Allergy as of 2023, this journal exemplifies excellence in research dissemination, positioning itself among the top 22% of relevant literature in the discipline. The journal, based in Switzerland, emphasizes its commitment to open science by ensuring all published research is freely accessible, fostering collaboration and innovation among researchers, professionals, and students alike. With substantial visibility demonstrated by its ranks within the Scopus database—ranked #52 out of 233 in Immunology and Allergy, and #58 out of 236 in Immunology and Microbiology—Frontiers in Immunology serves as a vital platform for cutting-edge research. Researchers are invited to contribute original investigations and reviews that expand the understanding of immune mechanisms, therapeutic advancements, and clinical applications, making it a cornerstone for those looking to push the boundaries of immunological science.

IMMUNOLOGY AND CELL BIOLOGY

Unveiling the Science Behind Immunity and Cell Function
Publisher: WILEYISSN: 0818-9641Frequency: 10 issues/year

IMUNOLOGY AND CELL BIOLOGY, published by Wiley, serves as a prominent platform for disseminating cutting-edge research in the fields of immunology and cell biology. With an ISSN of 0818-9641 and an E-ISSN of 1440-1711, this journal has established itself since its inception in 1987, demonstrating a commitment to advancing knowledge in its disciplines through high-quality articles. Renowned for its rigorous peer-review process, it holds a Q2 quartile ranking in both immunology and cell biology categories as of 2023, showing its competitive stature in these fields. IMUNOLOGY AND CELL BIOLOGY is indexed among the elite journals worldwide, with impressive Scopus rankings, including a rank of #75/233 in Immunology and Allergy. The journal’s comprehensive scope ensures that it caters to an audience of researchers, professionals, and students who are dedicated to exploring the intricate mechanisms of immune responses and cellular interactions. Although it does not operate under an open access model, its subscription-based content remains invaluable for those seeking to broaden their understanding of immunology and cell biology. By providing a forum for significant scientific dialogue, IMUNOLOGY AND CELL BIOLOGY continues to shape the future of research in these vital areas.

INTERNATIONAL JOURNAL OF ONCOLOGY

Shaping the future of cancer care through knowledge.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Science Immunology

Pioneering Insights in Immunology and Health
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: 2470-9468Frequency: 12 issues/year

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Catalyzing Knowledge in Clinical and Experimental Immunology
Publisher: OXFORD UNIV PRESSISSN: 0009-9104Frequency: 12 issues/year

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.